GlassScriptPhysician profile
Amandeep Singh
NPI 1154364149
$2,552.70
in general payments reported to CMS, 2019-2025
26 companies · $573 in 2025
The $573 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $136 · 2021: $206 · 2022: $213 · 2023: $679 · 2024: $509 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.08 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $506.80 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $320.83 | 2022-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $286.35 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $237.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $193.12 | 2023-2025 | |
| Glaxosmithkline, LLC. | $190.97 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $144.05 | 2019-2023 | Yupelri |
| Amgen INC. | $112.05 | 2023-2024 | Repatha, Otezla |
| Alexion Pharmaceuticals, INC. | $65.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.98 | 2019-2025 | Jardiance |
| Horizon Therapeutics Plc | $56.34 | 2020-2023 | Krystexxa |
| Gilead Sciences, INC. | $54.61 | 2019-2021 | |
| Abbott Laboratories | $38.41 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $36.56 | 2022 | |
| Lumenis, INC | $35.34 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $22.93 | 2021 | |
| Allergan, INC. | $22.57 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $21.54 | 2023 | Iovera, Zilretta |
| Medtronic, INC. | $21.00 | 2021 | |
| Philips North America LLC | $20.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $20.48 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.68 | 2022 | |
| Seqirus USA INC | $18.36 | 2025 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $16.89 | 2020 | |
| Corcept Therapeutics | $16.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.